AVDL
Avadel Pharmaceuticals plc
$21.64
+0.00
(+0.00%)
Mkt Cap
2.12B
Volume
35,016,239
52W Range
6.38-23.57
Sector
Healthcare
Beta
1.31
EPS (TTM)
0.00
P/E Ratio
108200.00
Revenue (TTM)
248.52M
Rev Growth (5Y)
+23.3%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$19.91
Overvalued
weak signal
8.7% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
18.9 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 169.12M | 27.96M | 0 | 0 | 22.33M | 59.22M | 103.27M | 172.74M | 150.25M | 173.21M | 14.78M | 22.44M |
| Net Income | (48.83M) | (160.28M) | (137.46M) | (77.33M) | 7.03M | (33.23M) | (95.30M) | 67.25M | (41.28M) | 40.66M | (84.91M) | (42.92M) |
| EPS | -0.51 | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.66 | -1.00 | 1.00 | -2.34 | -1.69 |
| Free Cash Flow | (46.91M) | (128.51M) | (71.02M) | (77.34M) | (48.83M) | (38.35M) | (102.89M) | (37.04M) | 17.70M | 82.66M | (12.35M) | (21.70M) |
| FCF / Share | -0.49 | -1.60 | -1.18 | -1.32 | -0.92 | -1.03 | -2.76 | -0.92 | 0.43 | 2.04 | -0.34 | -0.85 |
| Operating CF | (46.91M) | (128.51M) | (70.30M) | (77.31M) | (48.73M) | (38.33M) | (82.72M) | 16.66M | 18.90M | 84.29M | (10.62M) | (20.68M) |
| Total Assets | 164.24M | 164.70M | 132.78M | 247.26M | 311.64M | 151.44M | 190.30M | 252.11M | 245.48M | 214.98M | 174.21M | 116.25M |
| Total Debt | 1.70M | 2.62M | 131.02M | 145.00M | 130.52M | 124.65M | 115.84M | 267,000 | 815,000 | 1.12M | 118.48M | 85.70M |
| Cash & Equiv | 51.37M | 31.17M | 73.98M | 50.71M | 71.72M | 9.77M | 9.32M | 16.56M | 39.22M | 65.06M | 39.76M | 6.64M |
| Book Value | 73.85M | 87.74M | (21.14M) | 78.24M | 162.27M | (29.20M) | 2.78M | 84.56M | 42.07M | 67.86M | 24.89M | (9.51M) |
| Return on Equity | -0.66 | -1.83 | N/A | -0.99 | 0.04 | N/A | -34.28 | 0.80 | -0.98 | 0.60 | -3.41 | N/A |
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.47M | 68.13M | 52.51M | 50.41M | 50.02M | 41.50M | 27.18M | 19.45M | 7.01M | 1.50M | 0 | 0 |
| Net Income | 20,000 | 9.66M | (4.92M) | (5.04M) | (2.62M) | (13.82M) | (27.34M) | (28.79M) | (36.27M) | (64.43M) | (30.78M) | (27.45M) |
| EPS | 0.00 | 0.10 | -0.05 | -0.05 | -0.03 | -0.14 | -0.30 | -0.33 | -0.41 | -0.83 | -0.48 | -0.43 |
| Free Cash Flow | 23.25M | 12.52M | (8.23M) | 7.87M | (6.89M) | (18.19M) | (29.70M) | (28.03M) | (38.23M) | (32.02M) | (30.23M) | (16.08M) |
| FCF / Share | 0.24 | 0.13 | -0.09 | 0.08 | -0.07 | -0.19 | -0.32 | -0.33 | -0.43 | -0.41 | -0.47 | -0.25 |
| Operating CF | 23.26M | 12.70M | (8.23M) | 7.87M | (6.89M) | (18.19M) | (29.70M) | (28.03M) | (38.23M) | (32.02M) | (30.23M) | (15.37M) |
| Total Assets | 199.45M | 187.16M | 167.95M | 164.24M | 158.25M | 157.52M | 167.90M | 164.70M | 203.10M | 200.98M | 140.74M | 204.13M |
| Total Debt | 37.38M | 2.73M | 2.90M | 1.70M | 1.94M | 2.17M | 2.40M | 2.62M | 55.18M | 22.12M | 155.16M | 131.02M |
| Cash & Equiv | 79.81M | 63.40M | 56.37M | 51.37M | 28.58M | 28.85M | 35.79M | 31.17M | 51.81M | 49.98M | 83.39M | 73.98M |
| Book Value | 98.22M | 90.71M | 74.07M | 73.85M | 74.66M | 70.29M | 78.38M | 87.74M | 110.15M | 143.19M | (38.17M) | (21.14M) |
| Return on Equity | 0.00 | 0.11 | -0.07 | -0.07 | -0.04 | -0.20 | -0.35 | -0.33 | -0.33 | -0.45 | N/A | N/A |
AVDL News
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Cross Above 200-Day Moving Average – What’s Next?
Form 8.3 - Avadel Pharmaceuticals plc
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Form 8.3 -Avadel Pharmaceuticals plc
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing
Form 8.3 -Avadel Pharmaceuticals plc
Form 8.3 -Avadel Pharmaceuticals plc
Form 8.3 -Avadel Pharmaceuticals plc
Form 8.3 -Avadel Pharmaceuticals plc